HTBX Heat Biologics Inc

Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer, announced that the company is scheduled to present at the following investor conferences:

2016 Aegis Growth Conference

Date: Wednesday, September 21, 2016Time: 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time)Location: Encore at Wynn Las VegasWebcast: http://ir.heatbio.com/events-presentations.  The webcast will be archived on the company’s website for a period of three months.

OktoberINVESTfest 5th Annual Investors Conference

Date: Wednesday, September 28, 2016Time: 1:15 p.m. Eastern TimeLocation: The New York Academy of Sciences

About Heat Biologics, Inc. Heat Biologics, Inc. (Nasdaq:HTBX) is an immuno-oncology company developing novel therapies that activate a patient’s immune system against cancer.  Heat’s highly specific T cell-stimulating platform technologies, ImPACT and ComPACT, form the basis of its product candidates.  These platforms, in combination with other therapies, such as checkpoint inhibitors, are designed to address three distinct but synergistic mechanisms of action: robust activation of CD8+ “killer” T cells (one of the human immune system’s most potent weapons against cancer); reversal of tumor-induced immune suppression; and T cell co-stimulation to further enhance patients’ immune response.  Currently, Heat is conducting a Phase 2 trial with its HS-410 (vesigenurtacel-L) in patients with non-muscle invasive bladder cancer (NMIBC) and a Phase 1b trial with its HS-110 (viagenpumatucel-L) in combination with an anti-PD-1 checkpoint inhibitor to treat patients with non-small cell lung cancer (NSCLC).  For more information, please visit www.heatbio.com.

CONTACT:
For Investor Inquiries: 
David Waldman
919-240-7133
Investorrelations@heatbio.com

For Media Inquiries: 
Deanne Eagle 
Planet Communications 
917-837-5866
deanne@planetcommunications.nyc